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Purpose of the study
In this study we evaluated the efficacy of boosted and
unboosted ATV in different regimens in a cohort of HIV-1
infected patients.
Methods
The SCOLTA Project is a prospective, observational, mul-
ticenter study involving 24 infectious disease departments
created to assess the incidence of adverse events in
patients with HAART. In the SCOLTA database there are
also data about HAART efficacy and durability.
Summary of results
509 patients starting atazanavir were enrolled between
January 2003 and July 2007; 379 (74.5%) patients were
treated with boosted ATV and in the others 136 only with
ATV. At baseline, differences by sex, VL, CDC stage, pre-
treatment with PI, total durability of HAART, use of other
antiretroviral therapy, HBV co-infection were not statisti-
cally significant in the two groups. Patients with lower
CD4+ count received unboosted ATV more frequently.
Patients with boosted ATV were older (p = 0.01) and they
have less HCV co-infection (p = 0.04) and more lipodis-
trophy (p = 0.0002) than the others. These patients have
also total cholesterol (p = 0.02) and triglycerides (p =
0.002) levels higher than patients without ritonavir. The
last therapeutic regime did not influence the choice
between use of boosted ATV or not boosted.
Reasons of use for unboosted ATV were ritonavir intoler-
ance in 42.3% of cases, liver dysfunction in 6.2%, simpli-
fication of therapy in 9.2%, metabolic alteration in 2.3%,
poor compliance in 6.2%, availability of only ATV 200 mg
in 12.3%, and other reasons in 16.2%.
The follow-up time was 22.6 months in unboosted
patients and 24.3 months in boosted patients. At the end
of the follow-up time, 76/130 unboosted patients
(58.5%) and 220/379 boosted patients (58.1%) contin-
ued therapy. Respectively, 36 (27.7%) and 115 (30.3%)
patients withdrew therapy; patients lost to follow-up were
18 (13.9%) and 44 (11.6%), respectively. There are no
statistically significant differences between two groups
about suspension of therapy (death, virological failure,
adverse events, poor compliance and simplification).
At study end, CD4+ count and VL were not significantly
different between subjects still in treatment with boosted
and unboosted ATV. In unboosted patients lipidic profile
was better than in boosted patients but there are no statis-
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tically significant differences after adjustment for choles-
terol and triglycerides at baseline.
Conclusion
The study data show that, in clinical practice, both ATV-
containing regimens have same efficacy and durability.Page 2 of 2
(page number not for citation purposes)
